February 2, 2024 11:08 AM EST
News Briefing

Hutchmed's li­cens­ing deal, worth up to $227M; Tyra's $200 PIPE

Jaimy Lee

Deputy Editor

Plus, news about An­bo­gen Ther­a­peu­tics and Ve­ra Ther­a­peu­tics:

Hutchmed inks deal of up to $227.5M: The com­pa­ny is li­cens­ing two drugs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times